KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Cash & Current Investments (2017 - 2025)

Bionano Genomics' Cash & Current Investments history spans 7 years, with the latest figure at $13.3 million for Q3 2025.

  • For Q3 2025, Cash & Current Investments rose 11.52% year-over-year to $13.3 million; the TTM value through Sep 2025 reached $13.3 million, up 11.52%, while the annual FY2024 figure was $9.5 million, 85.81% down from the prior year.
  • Cash & Current Investments for Q3 2025 was $13.3 million at Bionano Genomics, down from $14.6 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $362.1 million in Q1 2021 and bottomed at $9.5 million in Q4 2024.
  • The 5-year median for Cash & Current Investments is $77.1 million (2023), against an average of $125.2 million.
  • The largest annual shift saw Cash & Current Investments soared 4345.69% in 2021 before it tumbled 86.47% in 2024.
  • A 5-year view of Cash & Current Investments shows it stood at $250.6 million in 2021, then tumbled by 54.84% to $113.2 million in 2022, then crashed by 41.01% to $66.8 million in 2023, then tumbled by 85.81% to $9.5 million in 2024, then soared by 40.7% to $13.3 million in 2025.
  • Per Business Quant, the three most recent readings for BNGO's Cash & Current Investments are $13.3 million (Q3 2025), $14.6 million (Q2 2025), and $18.2 million (Q1 2025).